참고문헌
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A (2015) Global cancer statistics,2012. CA Cancer J Clin 65, 87-108 https://doi.org/10.3322/caac.21262
- Youssef RF and Lotan Y (2011) Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal 11, 369-381 https://doi.org/10.1100/tsw.2011.28
- Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49, 466-465; discussion 475-467 https://doi.org/10.1016/j.eururo.2005.12.031
- Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178, 2314-2330 https://doi.org/10.1016/j.juro.2007.09.003
- Woldu SL, Bagrodia A and Lotan Y (2017) Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 119, 371-380 https://doi.org/10.1111/bju.13760
- van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56, 430-442 https://doi.org/10.1016/j.eururo.2009.06.028
- Chen Y, Zhu G, Wu K et al (2016) FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence. Tumour Biol 37, 4313-4321 https://doi.org/10.1007/s13277-015-4214-4
- Chang JC (2016) Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore) 95, S20-25 https://doi.org/10.1097/MD.0000000000004766
- Salehan MR and Morse HR (2013) DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 70, 31-40 https://doi.org/10.1080/09674845.2013.11669927
- Ryu J, Yoon NA, Seong H et al (2015) Resveratrol Induces Glioma Cell Apoptosis through Activation of Tristetraprolin. Mol Cells 38, 991-997 https://doi.org/10.14348/molcells.2015.0197
- Millour J, de Olano N, Horimoto Y et al (2011) ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 10, 1046-1058 https://doi.org/10.1158/1535-7163.MCT-11-0024
- Rosenfeldt MT, Bell LA, Long JS et al (2014) E2F1 drives chemotherapeutic drug resistance via ABCG2. Oncogene 33, 4164-4172 https://doi.org/10.1038/onc.2013.470
- Costa RH (2005) FoxM1 dances with mitosis. Nat Cell Biol 7, 108-110 https://doi.org/10.1038/ncb0205-108
- Kim SK, Roh YG, Park K et al (2014) Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Clin Cancer Res 20, 3233-3243 https://doi.org/10.1158/1078-0432.CCR-13-2761
- Park YY, Jung SY, Jennings NB et al (2012) FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33, 1843-1853 https://doi.org/10.1093/carcin/bgs167
- Nestal de Moraes G, Bella L, Zona S, Burton MJ and Lam EW (2016) Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance. Curr Drug Targets 17, 164-177 https://doi.org/10.2174/1389450115666141122211549
- Khongkow P, Gomes AR, Gong C et al (2016) Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene 35, 990-1002 https://doi.org/10.1038/onc.2015.152
- Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H and Teh MT (2010) Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res 70, 9515-9526 https://doi.org/10.1158/0008-5472.CAN-10-2173
- Zahreddine H and Borden KL (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4, 28
- Fletcher JI, Haber M, Henderson MJ and Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10, 147-156 https://doi.org/10.1038/nrc2789
- Ding XW, Wu JH and Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86, 631-637 https://doi.org/10.1016/j.lfs.2010.02.012
- Mo W and Zhang JT (2012) Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3, 1-27
- An Y and Ongkeko WM (2009) ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5, 1529-1542 https://doi.org/10.1517/17425250903228834
- Robey RW, To KK, Polgar O et al (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61, 3-13 https://doi.org/10.1016/j.addr.2008.11.003
- Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M and Ozen M (2014) Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate 74, 1498-1505 https://doi.org/10.1002/pros.22867
- Hu J, Li J, Yue X et al (2017) Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes. Oncotarget 8, 28463-28470
- Costa C, Pereira S, Lima L et al (2015) Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics. PLoS One 10, e0141253 https://doi.org/10.1371/journal.pone.0141253
- Natarajan K, Xie Y, Baer MR and Ross DD (2012) Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83, 1084-1103 https://doi.org/10.1016/j.bcp.2012.01.002
- Teh MT (2012) FOXM1 coming of age: time for translation into clinical benefits? Front Oncol 2, 146
- Damiani D, Tiribelli M, Geromin A et al (2015) ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. Am J Hematol 90, 784-789 https://doi.org/10.1002/ajh.24084
- Kim DH, Roh YG, Lee HH et al (2013) The E2F1 oncogene transcriptionally regulates NELL2 in cancer cells. DNA Cell Biol 32, 517-523 https://doi.org/10.1089/dna.2013.1974
피인용 문헌
- Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-5015-0
- The Dominant Role of Forkhead Box Proteins in Cancer vol.19, pp.10, 2018, https://doi.org/10.3390/ijms19103279
- CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression pp.00219541, 2018, https://doi.org/10.1002/jcp.27611